Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Says Safety Not A Factor In Dropping Lupus Development With Olumiant

Jan 28 2022

• By Joseph Haas

Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV - Image — Lilly may be backing away from label expansion plans for Olumiant in atopic dermatitis

Related Content

Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space

Jan 17 2022

Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

Jan 27 2021

Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance

Aug 16 2021

Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant

Nov 02 2020

Related Companies

Eli Lilly and Company

Incyte Corporation

AbbVie Inc.

Pfizer Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Additional Topics

Business Strategies Drug Approval Standards Clinical Trials Research & Development Dermatology BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window